MX2022001077A - Metodo para tratar la enfermedad de alzheimer mediante la regulacion del nivel de aminoacidos. - Google Patents

Metodo para tratar la enfermedad de alzheimer mediante la regulacion del nivel de aminoacidos.

Info

Publication number
MX2022001077A
MX2022001077A MX2022001077A MX2022001077A MX2022001077A MX 2022001077 A MX2022001077 A MX 2022001077A MX 2022001077 A MX2022001077 A MX 2022001077A MX 2022001077 A MX2022001077 A MX 2022001077A MX 2022001077 A MX2022001077 A MX 2022001077A
Authority
MX
Mexico
Prior art keywords
disease
amino acid
acid level
treating alzheimer
regulating
Prior art date
Application number
MX2022001077A
Other languages
English (en)
Inventor
Meiyu Geng
Jing Zhang
Guangqiang Sun
Xinyi Wang
Teng Feng
Original Assignee
Shanghai Green Valley Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Green Valley Pharmaceutical Co Ltd filed Critical Shanghai Green Valley Pharmaceutical Co Ltd
Publication of MX2022001077A publication Critical patent/MX2022001077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01005—Tyrosine transaminase (2.6.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporciona el uso de un agente para regular el nivel de aminoácidos en la preparación de un medicamento para tratar la enfermedad de Alzheimer en un sujeto.
MX2022001077A 2019-08-06 2020-08-05 Metodo para tratar la enfermedad de alzheimer mediante la regulacion del nivel de aminoacidos. MX2022001077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910720487.3A CN112336861A (zh) 2019-08-06 2019-08-06 通过调节氨基酸水平治疗阿尔茨海默病的方法
PCT/CN2020/107238 WO2021023241A1 (zh) 2019-08-06 2020-08-05 通过调节氨基酸水平治疗阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
MX2022001077A true MX2022001077A (es) 2022-04-26

Family

ID=74366465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001077A MX2022001077A (es) 2019-08-06 2020-08-05 Metodo para tratar la enfermedad de alzheimer mediante la regulacion del nivel de aminoacidos.

Country Status (11)

Country Link
US (1) US20220280589A1 (es)
EP (1) EP4011379A4 (es)
JP (1) JP2022543014A (es)
KR (1) KR20220044553A (es)
CN (2) CN112336861A (es)
AU (1) AU2020327259A1 (es)
BR (1) BR112022001700A2 (es)
CA (1) CA3148926A1 (es)
IL (1) IL290195A (es)
MX (1) MX2022001077A (es)
WO (1) WO2021023241A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112336742A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途
CN115808492A (zh) * 2021-09-14 2023-03-17 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物天冬酰胺及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160080C (zh) * 2001-10-01 2004-08-04 青岛海洋大学 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用
CN1562050A (zh) * 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
CN106344592A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
WO2018121559A1 (zh) * 2016-12-30 2018-07-05 上海绿谷制药有限公司 甘露糖醛二酸的组合物
WO2019074216A1 (ko) * 2017-10-13 2019-04-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법
CN108261425A (zh) * 2017-12-31 2018-07-10 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种减轻阿尔茨海默病的功能性低聚糖组合物及其制备方法与应用

Also Published As

Publication number Publication date
WO2021023241A9 (zh) 2021-11-04
AU2020327259A1 (en) 2022-03-10
CN112336861A (zh) 2021-02-09
JP2022543014A (ja) 2022-10-07
CA3148926A1 (en) 2021-02-11
EP4011379A1 (en) 2022-06-15
IL290195A (en) 2022-03-01
US20220280589A1 (en) 2022-09-08
EP4011379A4 (en) 2023-08-23
KR20220044553A (ko) 2022-04-08
BR112022001700A2 (pt) 2022-03-22
CN113891716A (zh) 2022-01-04
WO2021023241A1 (zh) 2021-02-11

Similar Documents

Publication Publication Date Title
MX2021007179A (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1).
PH12018500162A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2022001077A (es) Metodo para tratar la enfermedad de alzheimer mediante la regulacion del nivel de aminoacidos.
MX2019008690A (es) Compuestos espiro heterociclicos como inhibidores de magl.
MX2020009140A (es) Metodos para el tratamiento de enfermedades oculares.
EP4368169A3 (en) Use of sublingual dexmedetomidine for the treatment of agitation
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2020011845A (es) Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
MX2022001084A (es) Metodo de tratamiento de la enfermedad de alzheimer mediante la regulacion de microrganismos intestinales.
MX2019003733A (es) Tratamiento de cancer de prostata.
EP3708168A3 (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
NO20072631L (no) Kreftbehandlingsmetode
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2019003710A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2024003459A (es) Metodos de tratamiento de trastornos metabolicos.
JOP20200079A1 (ar) مثبطات مستقبل عامل نمو البشرة
MX2022001076A (es) Metodo para tratar la enfermedad de alzheimer mediante la inhibicion de la captacion de aminoacidos por las celulas t.
MX2023013972A (es) Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos.